贝利尤单抗治疗改善系统性红斑狼疮患者高密度脂蛋白的抗动脉粥样硬化特性
研究纳入35例常规治疗下仍处于活动期的系统性红斑狼疮(SLE)患者,在加用贝利尤单抗治疗6个月前后的血清样本,并与26名匹配健康对照比较。结果显示贝利尤单抗治疗后HDL胆固醇外流和抗氧化能力显著升高并恢复至对照水平,PON1活性升高、脂质过氧化产物降低,HDL脂质组学特征亦发生改变,作者认为贝利尤单抗可能改善SLE患者HDL抗动脉粥样硬化特性。
要点
- 活动期SLE患者HDL抗动脉粥样硬化特性受损,且HDL胆固醇外流与抗氧化能力与疾病活动度呈负相关。
- 加用贝利尤单抗治疗6个月后,SLE患者HDL胆固醇外流与抗氧化能力显著升高并恢复至健康对照水平。
- 贝利尤单抗治疗后HDL相关PON1活性升高、脂质过氧化产物降低,HDL脂质组学特征发生改变。
核心结论
- 活动期SLE患者的HDL显示受损的抗动脉粥样硬化特性,并伴有与对照不同的脂质组学特征。
- 贝利尤单抗治疗可能改善SLE患者HDL的抗动脉粥样硬化特性并改变HDL脂质组学特征,从而可能减轻动脉粥样硬化的发展。
研究设计与样本
- 研究采集35例常规治疗下仍处于活动期的SLE患者在加用贝利尤单抗治疗6个月前后的血清样本,并与26名匹配的健康个体比较。
主要发现
- 贝利尤单抗治疗后,SLE患者HDL的胆固醇外流和抗氧化能力显著升高,并恢复至对照受试者水平。
- 贝利尤单抗治疗后HDL相关PON1活性升高,脂质过氧化产物降低。
- HDL胆固醇外流和抗氧化能力与疾病活动度呈负相关。
- 贝利尤单抗治疗后SLE患者HDL脂质组学发生变化,SLE患者与健康个体之间亦存在差异,特定脂质种类的变化与HDL功能参数相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Chronic inflammatory diseases, like Systemic Lupus Erythematosus (SLE), carry an increased risk for atherosclerosis and cardiovascular events, accompanied by impairment of atheroprotective properties of high-density lipoprotein (HDL). In SLE, serum B cell-activating factor (BAFF), a cytokine implicated in disease progression, has been correlated with subclinical atherosclerosis. We investigated the impact of treatment with belimumab -an anti-BAFF monoclonal antibody- on HDL atheroprotective properties and composition in SLE patients. METHODS: Serum samples were collected from 35 SLE patients with active disease despite conventional therapy, before and after 6-month add-on treatment with belimumab, and 26 matched healthy individuals. We measured cholesterol efflux and antioxidant capacities, paraoxonase-1 (PON1) activity, serum amyloid A1 (SAA1), myeloperoxidase (MPO) and lipid peroxidation product levels of HDL. LC-MS/MS was performed to analyse the HDL lipidome. RESULTS: Following treatment with belimumab, cholesterol efflux and antioxidant capacities of HDL were significantly increased in SLE patients and restored to levels of control subjects. HDL-associated PON1 activity was also increased, whereas lipid peroxidation products were decreased following treatment. HDL cholesterol efflux and antioxidant capacities correlated negatively with the disease activity. Changes were noted in the HDL lipidome of SLE patients following belimumab treatment, as well as between SLE patients and healthy individuals, and specific changes in lipid species correlated with functional parameters of HDL. CONCLUSIONS: HDL of SLE patients with active disease displays impaired atheroprotective properties accompanied by distinct lipidomic signatures compared with controls. Belimumab treatment may improve the HDL atheroprotective properties and modify the HDL lipidomic signature in SLE patients, thus potentially mitigating atherosclerosis development.
引用
- Dedemadi AG, Gkolfinopoulou C, Nikoleri D, et al. Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment. Rheumatology (Oxford). 2025. PMID: 38514392. doi:10.1093/rheumatology/keae192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。